VVOS
Vivos Therapeutics, Inc.
NASDAQ · USHealthcareMedical - Devices
$0.41-1.98%
Price as of Jul 20, 2026
VVOS financials
Vivos Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M |
| Cost of revenue | $6.9M | $6.0M | $5.5M | $6.0M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M |
| Operating expenses | $30.4M | $20.2M | $25.6M | $35.0M |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M |
| EBITDA | -$19.9M | -$10.6M | -$13.0M | -$23.2M |
| Basic EPS | $-2.06 | $-2.22 | $-11.14 | $-25.90 |
| Diluted EPS | $-2.06 | $-2.22 | $-11.14 | $-25.90 |
| Balance sheet | ||||
| Cash & equivalents | $2.0M | $6.3M | $1.6M | $3.5M |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M |
| Stockholders’ equity | -$1.5M | $8.0M | $411.0K | $4.8M |
| Total debt | $13.5M | $1.5M | $2.0M | $2.4M |
| Net debt | $11.5M | -$4.7M | $352.0K | -$1.1M |
| Cash flow | ||||
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M |
| Capital expenditure | -$2.3M | -$568.0K | -$803.0K | -$924.0K |
| Free cash flow | -$17.6M | -$13.3M | -$12.7M | -$20.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |